Bayer is trading 4.01% up now at €50.10 as investors focus on the September 14, 2026 Missouri hearing for approval of Monsanto’s proposed $7.25 billion Roundup settlement.
- The hearing could resolve tens of thousands of claims and represents a major test of Bayer’s litigation strategy.
- Reuters reported the judge was not expected to issue an immediate ruling.
- Legal catalyst appears to outweigh the weak broader risk backdrop, with U.S. futures and major indexes trading lower.